FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040253531> ?p ?o ?g. }

• W2040253531 endingPage "1075" @default.
• W2040253531 startingPage "1067" @default.
• W2040253531 abstract "Summary Background Patients with chronic atrophic gastritis have long‐term gastric hypoacidity, and secondary hypergastrinaemia. Some also develop gastric ECL cells carcinoids (type 1 GC ). Most type 1 GC remain indolent, but some metastasise. Patients undergo surveillance, and some are treated with somatostatin analogues, endoscopic resection or surgery. Netazepide ( YF 476) is a highly selective, potent and orally active gastrin receptor antagonist, which has anti‐tumour activity in various rodent models of gastric neoplasia driven by hypergastrinaemia. Netazepide has been studied in healthy volunteers. Aim To assess the effect of netazepide on type 1 GC . Methods Eight patients with multiple type 1 GC received oral netazepide once daily for 12 weeks, with follow‐up at 12 weeks in an open‐label, pilot trial. Upper endoscopy was performed at 0, 6, 12 and 24 weeks, and carcinoids were counted and measured. Fasting serum gastrin and chromogranin A (CgA) and safety and tolerability were assessed at 0, 3, 6, 9, 12 and 24 weeks. Results Netazepide was well tolerated. All patients had a reduction in the number and size of their largest carcinoid. CgA was reduced to normal levels at 3 weeks and remained so until 12 weeks, but had returned to pre‐treatment levels at 24 weeks. Gastrin remained unchanged throughout treatment. Conclusions The gastrin receptor antagonist netazepide is a promising new medical treatment for type 1 gastric carcinoids , which appear to be gastrin‐dependent. Controlled studies and long‐term treatment are justified to find out whether netazepide treatment can eradicate type 1 gastric carcinoids ." @default.
• W2040253531 created "2016-06-24" @default.
• W2040253531 creator A5035774698 @default.
• W2040253531 creator A5046389093 @default.
• W2040253531 creator A5063920263 @default.
• W2040253531 creator A5070006227 @default.
• W2040253531 creator A5071544135 @default.
• W2040253531 creator A5079639200 @default.
• W2040253531 creator A5086979475 @default.
• W2040253531 date "2012-11-16" @default.
• W2040253531 modified "2023-10-17" @default.
• W2040253531 title "Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A" @default.
• W2040253531 cites W1564275998 @default.
• W2040253531 cites W1676960647 @default.
• W2040253531 cites W1964997023 @default.
• W2040253531 cites W1968697825 @default.
• W2040253531 cites W1970620056 @default.
• W2040253531 cites W1970633635 @default.
• W2040253531 cites W1972608806 @default.
• W2040253531 cites W1978756646 @default.
• W2040253531 cites W1985159645 @default.
• W2040253531 cites W1991644587 @default.
• W2040253531 cites W1995037065 @default.
• W2040253531 cites W1995375941 @default.
• W2040253531 cites W2000604473 @default.
• W2040253531 cites W2001047904 @default.
• W2040253531 cites W2001131794 @default.
• W2040253531 cites W2002142096 @default.
• W2040253531 cites W2011271268 @default.
• W2040253531 cites W2018275833 @default.
• W2040253531 cites W2019441870 @default.
• W2040253531 cites W2021478834 @default.
• W2040253531 cites W2032109348 @default.
• W2040253531 cites W2033006867 @default.
• W2040253531 cites W2048449971 @default.
• W2040253531 cites W2048539018 @default.
• W2040253531 cites W2062011075 @default.
• W2040253531 cites W2064893457 @default.
• W2040253531 cites W2068270752 @default.
• W2040253531 cites W2070624385 @default.
• W2040253531 cites W2074668854 @default.
• W2040253531 cites W2076486646 @default.
• W2040253531 cites W2080419869 @default.
• W2040253531 cites W2107362494 @default.
• W2040253531 cites W2109001875 @default.
• W2040253531 cites W2118522916 @default.
• W2040253531 cites W2120552892 @default.
• W2040253531 cites W2138900427 @default.
• W2040253531 cites W2144770516 @default.
• W2040253531 cites W2149656330 @default.
• W2040253531 cites W2150684511 @default.
• W2040253531 cites W2152314991 @default.
• W2040253531 cites W2158101446 @default.
• W2040253531 cites W2164406251 @default.
• W2040253531 cites W2170633201 @default.
• W2040253531 cites W2398548980 @default.
• W2040253531 doi "https://doi.org/10.1111/apt.12090" @default.
• W2040253531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23072686" @default.
• W2040253531 hasPublicationYear "2012" @default.
• W2040253531 type Work @default.
• W2040253531 sameAs 2040253531 @default.
• W2040253531 citedByCount "89" @default.
• W2040253531 countsByYear W20402535312012 @default.
• W2040253531 countsByYear W20402535312013 @default.
• W2040253531 countsByYear W20402535312014 @default.
• W2040253531 countsByYear W20402535312015 @default.
• W2040253531 countsByYear W20402535312016 @default.
• W2040253531 countsByYear W20402535312017 @default.
• W2040253531 countsByYear W20402535312018 @default.
• W2040253531 countsByYear W20402535312019 @default.
• W2040253531 countsByYear W20402535312020 @default.
• W2040253531 countsByYear W20402535312021 @default.
• W2040253531 countsByYear W20402535312022 @default.
• W2040253531 countsByYear W20402535312023 @default.
• W2040253531 crossrefType "journal-article" @default.
• W2040253531 hasAuthorship W2040253531A5035774698 @default.
• W2040253531 hasAuthorship W2040253531A5046389093 @default.
• W2040253531 hasAuthorship W2040253531A5063920263 @default.
• W2040253531 hasAuthorship W2040253531A5070006227 @default.
• W2040253531 hasAuthorship W2040253531A5071544135 @default.
• W2040253531 hasAuthorship W2040253531A5079639200 @default.
• W2040253531 hasAuthorship W2040253531A5086979475 @default.
• W2040253531 hasBestOaLocation W20402535311 @default.
• W2040253531 hasConcept C126322002 @default.
• W2040253531 hasConcept C134018914 @default.
• W2040253531 hasConcept C170493617 @default.
• W2040253531 hasConcept C186199130 @default.
• W2040253531 hasConcept C197934379 @default.
• W2040253531 hasConcept C204232928 @default.
• W2040253531 hasConcept C2776297358 @default.
• W2040253531 hasConcept C2776885963 @default.
• W2040253531 hasConcept C2776986829 @default.
• W2040253531 hasConcept C2777504413 @default.
• W2040253531 hasConcept C2778375690 @default.
• W2040253531 hasConcept C2778677798 @default.
• W2040253531 hasConcept C2779422922 @default.
• W2040253531 hasConcept C2780342937 @default.
• W2040253531 hasConcept C2781283050 @default.

• next